A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Rigosertib (Primary) ; Irinotecan; Oxaliplatin
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Onconova Therapeutics
- 31 Dec 2011 Actual patient number is 16 as reported by ClinicalTrials.gov.
- 13 Jul 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
- 13 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.